Madrigal Pharmaceuticals, Inc. has 1,073 employees, according to Revelio Labs workforce intelligence data. The YoY growth rate is 58.2%.
Data source: Revelio Labs Coverage: Global workforce Latest update: September 2025
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
As of September 2025
Madrigal Pharmaceuticals
workforce metrics
Headcount
1.1k
Avg. Salary
$198k
Tenure
1.6yr
Growth Rate
58.2%
Hiring Rate
Attrition Rate
For even more metrics data,
reach out to our sales team.
Interactive chart of Madrigal Pharmaceuticals annual worldwide employee count from 2023 to 2025.
Would you like to see the latest employee headcount data?
Would you like to see the latest employee geographic data?
Interactive chart of Madrigal Pharmaceuticals annual active job postings from 2023 to 2025.
Would you like to see the latest active job postings data?
Sentiment Topics
Would you like to see the latest employee sentiment data?